Biology at Work

Subscribe to updates

For immediate release
Jan 17, 2007

BellBrook Labs Introduces the Transcreener™ PDE Assay

Transcreener™ Assays rely on homogenous immunodetection of nucleotides, which means robust, generic detection of entire families of drug targets.  With the introduction of the Transcreener™ PDE Assay, BellBrook is extending nucleotide detection capabilities to include AMP and GMP detection.

Phosphodiesterases control a variety of cellular processes by hydrolyzing the
second messenger signaling molecules cAMP and cGMP. The Transcreener™ PDE Assay is a far-red, competitive fluorescence polarization immunoassay based on the detection of the hydrolyzed substrates AMP or GMP. Enzyme reaction progress is indicated by a decrease in the fluorescence polarization signal. The Transcreener™ PDE Assay is a simple two-step, endpoint assay (Fig. 1) accomodating cAMP/cGMP concentrations of 0.1 to 10 μM with a single reagent mix (up to 1 mM substrate has been used with Ab optimization). The assay provides an excellent signal under initial velocity conditions resulting in overall Z’> 0.6. Although originally designed for PDEs that hydrolyze cAMP or cGMP, the Transcreener™ PDE Assay can be use for any enzyme class that produces either AMP or GMP. Reduced development costs and accelerated drug discovery are achieved by utilizing this one simple streamlined screening method.

• Universal    Homogenous AMP or GMP detection

• Flexible       Any AMP or GMP producing enzyme

• Predictive   Rapid pharmacologically relevant data

• Sensitive    Z’ factor values > 0.6 under initial velocity conditions

• Smart        A single set of reagents reduces time and expense

All of these benefits mean one simple screening method, streamlined assays, reduced development costs and accelerated drug discovery.

Biology at Work

Call 866-313-7881 for more information or to order the Transcreener™ PDE Assay. Direct technical inquiries to info@bellbrooklabs.com.